Carcinoma in Situ of the Bladder

No AccessJournal of UrologyClinical Urology: Review Article1 Mar 1995Carcinoma in Situ of the Bladder M'Liss A. Hudson and Harry W. Herr M'Liss A. HudsonM'Liss A. Hudson and Harry W. HerrHarry W. Herr View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67650-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J. Urol.1952; 68: 261. Link, Google Scholar 2 : Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J. Urol.1952; 68: 763. Link, Google Scholar 3 : Carcinoma in situ: comments on the pathobiology of a paradox. Urol. Clin. N. Amer.1980; 7: 523. Google Scholar 4 : Carcinoma-in-situ of the urothelium. Urol. Clin. N. Amer.1976; 3: 87. Google Scholar 5 : Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol.1976; 116: 575. Link, Google Scholar 6 : Clinical observations in 69 cases of in situ carcinoma of the urinary bladder. Cancer Res.1977; 37: 2794. Google Scholar 7 : Carcinoma in situ. Urol. Clin. N. Amer.1992; 19: 499. Google Scholar 8 : Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res.1976; 36: 2495. Google Scholar 9 : Flat carcinoma in situ of the bladder. Brit. J. Urol.1976; 47: 829. Google Scholar 10 : The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J. Urol.1990; 144: 641. Google Scholar 11 : The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J. Urol.1974; 112: 68. Link, Google Scholar 12 : Muscularis mucosa of urinary bladder. Importance for staging and treatment. Amer. J. Surg. Path.1987; 11: 668. Google Scholar 13 : Paget's disease of the urethral meatus following transitional cell carcinoma of the bladder. J. Urol.1986; 135: 368. Abstract, Google Scholar 14 : Cytologic and histologic features of superficial bladder cancer. Urol. Clin. N. Amer.1992; 19: 435. Google Scholar 15 : Urine cytology in bladder tumors. Int. Surg.1991; 76: 52. Google Scholar 16 : Carcinogenesis in the human urinary bladder: observations after exposure to para-aminodiphenyl. New Engl. J. Med.1965; 272: 767. Google Scholar 17 : Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? J. Urol.1985; 134: 1115. Abstract, Google Scholar 18 : Prognostic significance of urine cytology on initial followup after intravesical mitomycin C for superficial bladder cancer. Cancer1986; 57: 2119. Google Scholar 19 : Comparative histopathology and deoxyribonucleic acid flow cytometry of random mucosal biopsies in untreated bladder carcinoma. J. Urol.1991; 145: 1164. Link, Google Scholar 20 : Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J. Urol.1992; 147: 11. Link, Google Scholar 21 : Bladder cancer from a perspective of 40 years. J. Cell Biochem.1992; 16: 23. Google Scholar 22 : Urine or bladder washings in the cytologic evaluation of transitional cell carcinoma of the urinary tract. A comparison made under routine conditions supplemented by flow cytometric DNA analysis. Scand. J. Urol. Nephrol.1987; 21: 119. Google Scholar 23 : Flow-cytometric deoxyribonucleic acid analysis of the human urinary bladder cancers with reference to histopathological findings. Eur. Urol.1992; 22: 153. Google Scholar 24 : Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications. J. Urol.1992; 148: 44. Link, Google Scholar 25 : Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res.1990; 50: 7081. Google Scholar 26 : Molecular alternations in superficial and locally advanced human bladder cancer. Cancer Res.1991; 51: 5405. Google Scholar 27 : Genetic alterations in bladder cancer. Lancet1993; 342: 469. Google Scholar 28 : Role of chromosome 9 in human bladder cancer. Cancer Res.1993; 53: 4066. Google Scholar 29 : Identification of p53 gene mutations in bladder cancers and urine samples. Science1991; 252: 706. Google Scholar 30 : Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol.1994; 152: 388. Link, Google Scholar 31 : Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. Brit. J. Cancer1990; 62: 762. Google Scholar 32 : Markers of prognosis in superficial bladder cancer. Sem. Urol.1992; 10: 28. Google Scholar 33 : Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer1992; 69: 1212. Google Scholar 34 : Detection of autocrine motility factor in urine as a marker of bladder cancer. J. Natl. Cancer Inst.1988; 80: 1203. Google Scholar 35 : Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody KI-67. J. Urol.1990; 144: 875. Link, Google Scholar 36 : Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group. Cancer Res.1990; 50: 432. Google Scholar 37 : Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin, cytokeratin) in transitional cell carcinoma of the bladder. Urol. Int.1992; 48: 14. Google Scholar 38 : Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens. J. Urol.1980; 123: 22. Link, Google Scholar 39 : Immunoanatomic distribution of blood group antigens in the human urinary tract: influence of secretor status. Lab. Invest.1986; 55: 444. Google Scholar 40 : The relationship of ABH(O) blood group antigen expression in intraepithelial dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder. Cancer1991; 64: 1661. Google Scholar 41 : Clinical assessment of carcinoma in situ of the human urinary bladder. Int. Urol. Nephrol.1992; 24: 243. Google Scholar 42 : Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J. Urol.1990; 143: 285. Link, Google Scholar 43 : The Lewis X antigen as a predictor of tumor recurrence in high risk disease-free, bladder cancer patients. J. Urol.1992; 147: 423A. abstract 841. Google Scholar 44 : Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. Cancer Res.1988; 48: 4113. Google Scholar 45 : The plight of the patient with carcinoma in situ of the bladder. J. Urol.1970; 103: 160. Link, Google Scholar 46 : Management of bladder cancer. Curr. Prob. Cancer1979; 4: 1. Google Scholar 47 : Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J. Urol.1986; 135: 265. Link, Google Scholar 48 : Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. CA1993; 43: 351. Google Scholar 49 : Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J. Urol.1983; 130: 677. Link, Google Scholar 50 : Histology and fine structure of the muscularis mucosae of the human urinary bladder. J. Anat.1983; 136: 265. Google Scholar 51 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med.1991; 325: 1205. Google Scholar 52 : BCG therapy alters the progression of superficial bladder cancer. J. Clin. Oncol.1988; 6: 1450. Google Scholar 53 : Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. J. Urol.1990; 143: 34. Link, Google Scholar 54 : 5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management. J. Urol.1987; 138: 1158. Link, Google Scholar 55 : The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J. Urol.1981; 125: 307. Link, Google Scholar 56 : The results of conservative treatment in patients with carcinoma in situ of the bladder. Proc. Amer. Soc. Clin. Oncol.1982; 1: 183. abstract 424. Google Scholar 57 : A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Brit. J. Urol.1983; 55: 676. Google Scholar 58 : Mitomycin C intravesical therapy in noninvasive bladder cancer after failure of thiotepa. Cancer1984; 53: 1025. Google Scholar 59 : Experience with mitomycin-C in superficial bladder cancer: preliminary results of intravesical administration to prevent recurrences. In: Controlled Clinical Trials in Urologic Oncology. Edited by . New York: Raven Press1984: 279. Google Scholar 60 : Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. J. Urol.1985; 134: 1107. Link, Google Scholar 61 : Mitomycin C for patients who failed thiotepa. The National Bladder Cancer Group. Urology, suppl. 41985; 26: 30. Google Scholar 62 : Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. Eur. Urol.1986; 12: 32. Google Scholar 63 : Intravesical therapy of low stage bladder carcinoma with mitomycin C. J. Urol.1986; 135: 186A. abstract 329. Google Scholar 64 : Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. Brit. J. Urol.1987; 59: 239. Google Scholar 65 : Editorial comment. J. Urol.1990; 143: 36. Google Scholar 66 : Chemotherapy in bladder cancer. Urol. Res.1978; 6: 263. Google Scholar 67 : Intravesical therapy with adriamycin in patients with superficial bladder tumors. Eur. Urol.1980; 6: 132. Google Scholar 68 : Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J. Urol.1981; 125: 185. Google Scholar 69 : Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin). Cancer Chemother. Pharmacol.1983; 11: S35. Google Scholar 70 : Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder. Scand. J. Urol. Nephrol.1984; 18: 131. Google Scholar 71 : Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized, prospective study in 202 patients with superficial bladder cancer. J. Urol.1990; 143: 502. Google Scholar 72 : Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (Immunocyst). Dev. Biol. Standardization1992; 77: 229. Google Scholar 73 : Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder. In: Immunotherapy of Urological Tumours. Edited by . New York: Churchill Livingstone1990: 13. Google Scholar 74 : BCG in superficial bladder cancer: a review of phase III European trials. Eur. Urol.1992; 21: 7. Google Scholar 75 : Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. Cancer Chemother. Pharmacol.1992; 30: S37. Google Scholar 76 : The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J. Urol.1985; 134: 36. Link, Google Scholar 77 : Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin-C. J. Urol.1987; 137: 871. Abstract, Google Scholar 78 : The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin. J. Urol.1985; 133: 598. Link, Google Scholar 79 : Treatment of carcinoma in situ of the bladder with BCG: a phase II trial. Cancer Immunol. Immunother.1980; 9: 69. Google Scholar 80 : Carcinoma in situ of the bladder. Sem. Urol.1983; 1: 15. Google Scholar 81 : Bacillus Calmette-Guerin immunotherapy in bladder cancer. J. Urol.1985; 134: 40. Abstract, Google Scholar 82 : Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol.1985; 134: 48. Link, Google Scholar 83 : Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. J. Urol.1986; 135: 261. Link, Google Scholar 84 : Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J. Urol.1988; 139: 935. Link, Google Scholar 85 : Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. In: EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer. Edited by . New York: Alan R. Liss, Inc.1989: 271. Google Scholar 86 : The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ. In: BCG in Superficial Bladder Cancer. Edited by . New York: Alan R. Liss, Inc.1989: 193. Google Scholar 87 : Immunopathological effects of intravesical BCG therapy. In: BCG in Superficial Bladder Cancer. Edited by . New York: Alan R. Liss, Inc.1989: 93. Google Scholar 88 : Long-term effect of intravesical bacillus Calmetter-Guerin (BCG) Tice strain on flat carcinoma in situ of the bladder. In: BCG in Superficial Bladder Cancer. Edited by . New York: Alan R. Liss1989: 171. Google Scholar 89 : Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J. Urol.1990; 144: 652. Link, Google Scholar 90 : Intravesical BCG therapy in patients with superficial bladder tumors. In: EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer. Edited by . New York: Alan R. Liss, Inc.1989: 153. Google Scholar 91 : Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur. Urol.1991; 19: 97. Google Scholar 92 : Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol.1989; 141: 22. Link, Google Scholar 93 : Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette-Guerin. Brit. J. Urol.1992; 70: 271. Google Scholar 94 : Radical cystectomy--often too late? Eur. Urol.1987; 13: 361. Google Scholar 95 : Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl. Brit. J. Urol.1979; 51: 545. Google Scholar 96 : Randomized trial of high vs. low dose intravesical interferon alpha-2-b (IFN-A2B) treatment of bladder carcinoma in situ (CIS). Proc. Amer. Soc. Clin. Oncol.1988; 7: 121. abstract 467. Google Scholar 97 : Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J. Urol.1992; 147: 601. Abstract, Google Scholar 98 : Urological audit: the role for an aggressive approach to high grade superficial bladder tumours. Brit. J. Urol.1992; 70: 156. Google Scholar 99 : Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J. Urol.1992; 148: 797. Link, Google Scholar 100 : Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol.1992; 147: 1020. Link, Google Scholar 101 : Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. Urol.1994; 152: 367. Link, Google Scholar 102 : Upper tract disease following intravesical BCG for superficial bladder cancer: five year follow-up. J. Urol.1992; 147: 273A. abstract 237. Google Scholar 103 : Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma. Urology1992; 40: 509. Google Scholar 104 : Superficial bladder cancer treated by total cystectomy: tumour characteristics and patient survival. Int. Urol. Nephrol.1992; 24: 265. Google Scholar 105 : Importance of early treatment of transitional cell carcinoma of prostatic ducts. Urology1988; 32: 11. Google Scholar 106 : Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J. Urol.1977; 118: 399. Link, Google Scholar Division of Urological Surgery, Washington University School of Medicine, St. Louis, Missouri and Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMossberg A, Hou Y, Svensson M, Holmqvist B and Svanborg C (2018) HAMLET Treatment Delays Bladder Cancer DevelopmentJournal of Urology, VOL. 183, NO. 4, (1590-1597), Online publication date: 1-Apr-2010.Chade D, Shariat S, Adamy A, Bochner B, Donat S, Herr H and Dalbagni G (2018) Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In SituJournal of Urology, VOL. 184, NO. 2, (464-469), Online publication date: 1-Aug-2010.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.DONAT S, NORTH A, DALBAGNI G and HERR H (2018) Efficacy of Office Fulguration for Recurrent Low Grade Papillary Bladder Tumors Less Than 0.5 cmJournal of Urology, VOL. 171, NO. 2, (636-639), Online publication date: 1-Feb-2004.HALLING K, KING W, SOKOLOVA I, KARNES R, MEYER R, POWELL E, SEBO T, CHEVILLE J, CLAYTON A, KRAJNIK K, EBERT T, NELSON R, BURKHARDT H, RAMAKUMAR S, STEWART C, PANKRATZ V, LIEBER M, BLUTE M, ZINCKE H, SEELIG S, JENKINS R and O'KANE D (2018) A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in UrineJournal of Urology, VOL. 167, NO. 5, (2001-2006), Online publication date: 1-May-2002.DUREK C, RICHTER E, BASTECK A, RÜSCH-GERDES S, GERDES J, JOCHAM D and BÖHLE A (2018) THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATIONJournal of Urology, VOL. 165, NO. 5, (1765-1768), Online publication date: 1-May-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.DUGGAN B, KELLY J, KEANE P and JOHNSTON S (2018) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, VOL. 165, NO. 3, (946-954), Online publication date: 1-Mar-2001.HALLING K, KING W, SOKOLOVA I, MEYER R, BURKHARDT H, HALLING A, CHEVILLE J, SEBO T, RAMAKUMAR S, STEWART C, PANKRATZ S, O'KANE D, SEELIG S, LIEBER M and JENKINS R (2018) A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, VOL. 164, NO. 5, (1768-1775), Online publication date: 1-Nov-2000.STEINBERG G, BAHNSON R, BROSMAN S, MIDDLETON R, WAJSMAN Z and WEHLE M (2018) EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 163, NO. 3, (761-767), Online publication date: 1-Mar-2000.LOSA A, HURLE R and LEMBO A (2018) LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTSJournal of Urology, VOL. 163, NO. 1, (68-72), Online publication date: 1-Jan-2000.Koenig F, McGovern F, Althausen A, Deutsch T and Schomacker K (2018) Laser Induced Autofluorescence Diagnosis of Bladder CancerJournal of Urology, VOL. 156, NO. 5, (1597-1601), Online publication date: 1-Nov-1996.Lundholm C, Norlen B, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, Olsson J, Tveter K, Westberg R and Malmstrom P (2018) A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 156, NO. 2, (372-376), Online publication date: 1-Aug-1996.Manyak M (2018) Editorial: Bladder Carcinoma--The Good, The Bad and The UglyJournal of Urology, VOL. 155, NO. 1, (103-104), Online publication date: 1-Jan-1996. Volume 153Issue 3March 1995Page: 564-572 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information M'Liss A. Hudson More articles by this author Harry W. Herr More articles by this author Expand All Advertisement PDF downloadLoading ...